Eli Lilly's drug, donanemab, has shown promise in slowing the progression of Alzheimer's disease by targeting beta amyloid, but has significant side effects including dangerous brain swelling. The drug reduced cognitive decline by 32% in clinical trials and will undergo the process of being approved for use in hospitals. The BBC website features articles, videos, and audio content on various topics and provides information on its terms of use, privacy policy, and accessibility options.